Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -35.69% is 56% above its 5-year average of -80.91%, near the high end of its 5-year range (-156.33%–-19.01%).
13.96% above its 12-month average of -41.48%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -19.01%.
NET PROFIT MARGIN
-35.69%
NET PROFIT MARGIN AVG TTM
-41.48%
NET PROFIT MARGIN AVG 3Y
-58.63%
NET PROFIT MARGIN AVG 5Y
-80.91%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.96%
CURRENT VS 3Y AVG
+39.13%
CURRENT VS 5Y AVG
+55.89%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-10097.14%
vs the sector median at left
Sight Sciences, Inc.
Market Cap
$465.75M
Net Profit Margin
-35.69%
TTM Avg
-41.48%
3Y Avg
-58.63%
5Y Avg
-80.91%
Market Cap
$469.12M
Net Profit Margin
-38.37%
TTM Avg
-56.73%
3Y Avg
-82.08%
5Y Avg
-57.25%
Market Cap
$471.57M
Net Profit Margin
-3.06%
TTM Avg
-9.59%
3Y Avg
-17.39%
5Y Avg
-29.37%
Market Cap
$471.65M
Net Profit Margin
2.94%
TTM Avg
-53.14%
3Y Avg
-197.29%
5Y Avg
-267.69%
Market Cap
$472.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$475.91M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
11.36%
5Y Avg
9.09%
Market Cap
$483.54M
Net Profit Margin
11.55%
TTM Avg
13.38%
3Y Avg
8.98%
5Y Avg
-0.37%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | $465.75M | -35.69% | -41.48% | -58.63% | -80.91% |
| Kamada Ltd. (KMDA)vs › | $467.90M | 11.60% | 10.09% | 6.05% | 5.82% |
| Alpha Teknova, Inc. (TKNO)vs › | $469.12M | -38.37% | -56.73% | -82.08% | -57.25% |
| Cerus Corporation (CERS)vs › | $471.57M | -3.06% | -9.59% | -17.39% | -29.37% |
| Arvinas, Inc. (ARVN)vs › | $471.65M | 2.94% | -53.14% | -197.29% | -267.69% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | 0.00% | 0.00% | 0.00% | 0.00% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | 0.00% | 0.00% | 11.36% | 9.09% |
| NRC Health (NRC)vs › | $452.54M | 4.18% | 12.88% | 16.89% | 20.14% |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 11.55% | 13.38% | 8.98% | -0.37% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | 0.00% | -90.86% | -351.90% | -2330.90% |
Operating Margin
-48.0%
Net Profit Margin
-35.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -19.01% |
| 2026-03-31 | -65.90% |
| 2025-12-31 | -20.42% |
| 2025-09-30 | -41.04% |
| 2025-06-30 | -61.04% |
| 2025-03-31 | -80.84% |
| 2024-12-31 | -62.11% |
| 2024-09-30 | -54.90% |
| 2024-06-30 | -57.69% |
| 2024-03-31 | -84.43% |
| 2023-12-31 | -57.02% |
| 2023-09-30 | -65.15% |
| 2023-06-30 | -62.86% |
| 2023-03-31 | -90.67% |
| 2022-12-31 | -82.30% |
| 2022-09-30 | -119.02% |
| 2022-06-30 | -138.39% |
| 2022-03-31 | -156.33% |
| 2021-12-31 | -108.52% |
| 2021-09-30 | -131.05% |
| 2021-06-30 | -140.53% |
| 2021-03-31 | -141.75% |
| 2020-12-31 | -101.27% |
| 2020-09-30 | -93.60% |
| 2020-06-30 | -237.46% |
| 2020-03-31 | -141.24% |
